Significant Insider Change: NxStage Medical, Inc. (NASDAQ:NXTM) SVP and General Counsel Winifred Swan, Sold $76,530 in Stock

November 23, 2016 - By Linda Rogers

Significant Insider Change: NxStage Medical, Inc. (NASDAQ:NXTM) SVP and General Counsel Winifred Swan, Sold $76,530 in Stock

Winifred Swan Insider Sell

Winifred Swan, the SVP and General Counsel of Nxstage Medical Inc, made a sale of 3,000 shares of the company, with their total value being placed at $76,530 U.S. Dollars, based on a market price of $25.5 for share. The public report was disclosed on November 22, 2016 with the U.S. SEC and is now freely available for public review here. Winifred Swan now owns 11,973 shares of the Company.

NxStage Medical, Inc. (NASDAQ:NXTM) Ratings Coverage

Out of 6 analysts covering NxStage Medical (NASDAQ:NXTM), 5 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 83% are positive. $30 is the highest target while $14 is the lowest. The $23.10 average target is -5.68% below today’s ($24.49) stock price. NxStage Medical has been the topic of 7 analyst reports since November 4, 2015 according to StockzIntelligence Inc. The rating was initiated by BTIG Research on Friday, December 18 with “Buy”. Northland Capital upgraded the shares of NXTM in a report on Tuesday, June 28 to “Outperform” rating. Sterne Agee CRT initiated the stock with “Buy” rating in Friday, December 11 report. The stock has “Overweight” rating given by Piper Jaffray on Thursday, March 31. As per Tuesday, August 2, the company rating was maintained by Canaccord Genuity.

Insitutional Activity: The institutional sentiment increased to 1.2 in 2016 Q2. Its up 0.23, from 0.97 in 2016Q1. The ratio is positive, as 22 funds sold all NxStage Medical, Inc. shares owned while 45 reduced positions. 26 funds bought stakes while 39 increased positions. They now own 61.50 million shares or 4.11% more from 59.07 million shares in 2016Q1.

The Ontario – Canada-based Mackenzie Financial Corporation has invested 0% in NxStage Medical, Inc. (NASDAQ:NXTM). Moreover, First Republic Inv Mgmt has 0% invested in NxStage Medical, Inc. (NASDAQ:NXTM) for 11,697 shares. First Light Asset Mgmt Limited Liability has 254,113 shares for 2.55% of their US portfolio. Teachers Advsrs Inc accumulated 112,655 shares or 0% of the stock. Tiaa Cref Investment Limited Com owns 239,148 shares or 0% of their US portfolio. Hbk Invs Lp has invested 0.01% of its portfolio in NxStage Medical, Inc. (NASDAQ:NXTM). Balyasny Asset Mngmt Limited Co has 0% invested in the company for 10,566 shares. Dafna Management Ltd Liability owns 356,509 shares or 6.13% of their US portfolio. Whittier Trust accumulated 2,750 shares or 0% of the stock. California Public Employees Retirement Sys last reported 128,800 shares in the company. Cortina Asset Management Ltd Liability Com owns 1.72 million shares or 1.69% of their US portfolio. Credit Suisse Ag holds 78,203 shares or 0% of its portfolio. Moreover, Osterweis Cap Mngmt Incorporated has 0.14% invested in NxStage Medical, Inc. (NASDAQ:NXTM) for 102,632 shares. D E Shaw & reported 244,348 shares or 0.01% of all its holdings. Aqr Capital Limited Liability Company holds 0% or 18,387 shares in its portfolio.

Insider Transactions: Since September 12, 2016, the stock had 0 insider buys, and 4 sales for $799,539 net activity. Turk Joseph E Jr sold $590,850 worth of stock or 22,500 shares. MOORE CRAIG W also sold $69,930 worth of NxStage Medical, Inc. (NASDAQ:NXTM) on Monday, September 12. 4,300 NxStage Medical, Inc. (NASDAQ:NXTM) shares with value of $112,789 were sold by TOWSE MATTHEW W.

The stock decreased 5.19% or $1.34 during the last trading session, hitting $24.49. About 676,148 shares traded hands or 74.69% up from the average. NxStage Medical, Inc. (NASDAQ:NXTM) has risen 63.69% since April 20, 2016 and is uptrending. It has outperformed by 59.13% the S&P500.

NxStage Medical, Inc. is a medical technology company. The company has a market cap of $1.56 billion. The Firm is engaged in the development, manufacturing and marketing of services and products for patients suffering from chronic or acute kidney failure. It currently has negative earnings. The Firm operates through three divisions: System One, In-Center and Services.

According to Zacks Investment Research, “NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure.”

More recent NxStage Medical, Inc. (NASDAQ:NXTM) news were published by: Fool.com which released: “Here’s Why NxStage Medical, Inc.’s Stock Is Popping Today” on November 03, 2016. Also Fool.com published the news titled: “Home and Critical Care Drive NxStage Medical, Inc. Q2 Improvement” on August 04, 2016. Fool.com‘s news article titled: “Why NxStage Medical, Inc. Guided Lower Today” with publication date: February 10, 2016 was also an interesting one.

NXTM Company Profile

NxStage Medical, Inc., incorporated on October 20, 1998, is a medical technology company. The Firm is engaged in the development, manufacturing and marketing of services and products for patients suffering from chronic or acute kidney failure. The Firm operates through three divisions: System One, In-Center and Services. The Firm offers its services and products to various markets, such as home, critical care and in-center. The Company’s primary product, the System One, delivers the therapeutic flexibility and clinical benefits associated with dialysis machines that can be used by healthcare professionals and trained lay users alike in various settings, including patient homes, as well as traditional care settings, such as hospitals and dialysis centers. The Firm operates NxStage Kidney Care dialysis centers that treat end-stage renal disease patients directly.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>